Search
Search Results
##search.searchResults.foundPlural##
-
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3239PDF: 932HTML: 2952 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2105PDF: 1685HTML: 374 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2091PDF: 986HTML: 4068Cover Letter: 219Figure 1: 230Figure 2: 229Table 1: 203 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1821PDF: 714HTML: 2103Untitled: 213Untitled: 152Untitled: 168Untitled: 153Untitled: 163Untitled: 176Untitled: 183 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1032PDF: 1152Suppl. Files: 569HTML: 83 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
2937PDF: 888HTML: 1755 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
764PDF: 84HTML: 135 -
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
1949PDF: 818HTML: 2197Table 1: 175Table 2: 194Table 3: 187Table 4: 189Table 5: 187Tble 6: 179Cover Letter: 201Greene Tab.7: 187 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2832PDF: 846HTML: 6518Untitled: 224Untitled: 187Untitled: 201Untitled: 209 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
1685PDF: 1094HTML: 10694Untitled: 187 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1171PDF: 828HTML: 3358 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2024PDF: 818HTML: 210 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3540PDF: 1477HTML: 4385CoverLetter: 183Figure1: 194 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1329PDF: 822HTML: 129 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2568PDF: 735HTML: 2296 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1753PDF: 1068HTML: 245 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2438PDF: 1297HTML: 1746CoverLetter: 178 -
A Case of Rupioid Syphilis Masquerading as Aggressive Cutaneous Lymphoma
2193PDF: 941HTML: 5059Cover Letter: 168Figure 2: 160Figure 1: 172Figure 3: 194Figure 4: 166Figure Legend: 184Table 1: 186Table 2: 179Table 3: 178 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1299PDF: 1195HTML: 445 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3538PDF: 2402HTML: 1458 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2593PDF: 1605HTML: 2354Table1: 188 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3576PDF: 877HTML: 6710 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1255PDF: 482HTML: 136 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1450PDF: 1051HTML: 215 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1109PDF: 483HTML: 229 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4084PDF: 1579HTML: 940 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2211PDF: 1040HTML: 1981Characteristic of study group: 196 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2574PDF: 797HTML: 5209 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1601PDF: 804HTML: 161 -
Mantle cell lymphoma relapsing at the lymphedematous arm.
1691PDF: 693HTML: 3795 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3864PDF: 1469HTML: 8510 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2161PDF: 1578HTML: 263 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1710PDF: 1160HTML: 244







